Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR

Leukemia

Volumn 17, Issue 5, 2003, Pages 821-828

  Hui, C H ^a   Goh, K Y ^b   White, D ^a   Branford, S ^a   Grigg, A ^c   Seymour, J F ^d   Kwan, Y L ^e   Walsh, S ^a   Hoyt, R ^c   Trickett, A ^e   Rudzki, B ^a   Ma, D D F ^b   To, L B ^a,f   Hughes, T P ^a,f  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e ST GEORGE HOSPITAL   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Autologous peripheral blood stem cells; Complete cytogenetic responders; Efficacy and safety; Imatinib; Quantitative RT PCR

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HYDROXYUREA; IMATINIB; INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; APHERESIS; ARTICLE; CELL COUNT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOGENETICS; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; STEM CELL MOBILIZATION;

EID: 0038189835     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402917     Document Type: Article

References (40)

1. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J et al. Autologous transplants for chronic myeloid leukemia: results from eight transplant groups. Lancet 1994; 343: 1486-1488.
2. Bergamaschi G, Podesta M, Frassoni F, Rosti V, Carella AM, Saglio G et al. Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukemia autografted with Ph-negative stem cells. Br J Haematol 1994; 87: 867-870.
3. Bhatia R, Verfaillie CM, Miller JS, McGlave PB. Autologous transplantation therapy for chronic myeloid leukaemia. Blood 1997; 89: 2623-2634.
4. Carella AM, Celesti L, Lerma E, Dejana A, Frassoni F. Stem-cell mobilization for autografting in chronic myeloid leukemia. Blood Rev 1997; 11: 154-159.
5. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation in CML. Blood 1994; 83: 3068-3076.
6. Singer IO, Franklin IM. Autografting as first line treatment for chronic myeloid leukaemia. J Clin Pathol 1998-51: 92-95.
7. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
8. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346: 683-693.
9. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001; 344: 1038-1042.
10. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
11. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
12. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
13. Branford S, Moore S, Grigg A, Szer J, Arthur C, Taylor K et al. Early measurement of BCR-ABL mRNA blood levels may be predictive of subsequent achievement of major cytogenetic response to Glivec in chronic myeloid leukemia. Blood 2001; 98: 613a.
14. Stentoft J, Pallisgaard N, Kjeldsen E, Holm MS, Nielsen JL, Hokland P. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukaemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol 2001; 67:302-308.
15. Druker BJ for the IRIS Study Group. STI571 (Glivec imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomised study. Proc Am Soc Clin Oncol 2002; 21: 1a.
16. Goldman JM, Druker BJ. Chronic myeloid leukaemia: current treatment options. Blood 2001; 19: 2039-2042.
17. Goldman J. Implications of imatinib mesylate for hematopoietic stem cell transplantation. Semin Hematol 2001; 38 (Suppl. 8): 28-34.
18. Apperley JF. Up-front transplantation for chronic myeloid leukaemia. 7th Congress of the European Hematology Association. The Hematol J 2002; Educational programme: 96-100.
19. O'Brien SG, Rule SAJ. Position paper on imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 119: 268-272.
20. Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α. Leukemia 2002; 16: 1579-1583.
21. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
22. von Bubnoff N, Schneller F, Peschel C, Duyster J. Bcr-abl gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487.
23. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472-3475.
24. Hochhaus A, Kreil S, Corbin AS, La Rosé P, Müller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
25. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigier AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-932.
26. Lennard AL, Clark RE, Drummond MW, Rule S, Bolam S, Martin D on behalf of the MRC CML Working Party. Collection of peripheral blood stem cells in chronic myeloid leukaemia (CML) patients Philadelphia negative after treatment with imatinib mesylate (Glivec). Br J Haematol 2002; 117 (Suppl 1) 14.
27. Chang A, Ma DDF. The influence of flow cytometric gating strategy on the standardisation of CD34+ cell quantitation: an Australian multi-center study. Australasian BMT Scientists Study Group. J Hematother 1996; 5: 605-616.
28. Holland PM, Abrahamson RD, Watson R, Will S, Saiki RK, Gelfand DH. Detection of specific polymerase chain reaction products by utilizing the 5′ to 3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Nat Acad Sci USA 1991; 88: 7276-7280.
29. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107: 587-599.
30. Hughes TP, Grigg A, Szer J, Ho J, Ma D, Dale BM et al. Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHU-GCSG in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. Br J Haematol 1997; 96: 635-640.
31. Deininger M, Pönisch W, Krahl R, Leiblein S, Edel E, Lange T et al. for the East German Study Group Haematology/Oncology. Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens. Bone Marrow Transplantation 2001; 27: 1125-1132.
32. Archimbaud E, Michallet M, Philip I, Charrin C, Clapisson G, Belhabri A et al. Granulocyte colony-stimulating factor given in addition to interferon-alpha to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia. Br J Haematol 1997; 99: 678-684.
33. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99: 3792-3800.
34. Morrison SJ, Wright DE, Weissman IL. Cyclophosphamide / granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilisation. Proc Nat Acad Sci USA 1997; 94: 1908-1913.
35. Roberts MM, Swart BW, Simmons PJ, Basser RL, Begley CG, To LB. Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor. Br J Haematol 1999; 104: 778-784.
36. Sawyers CL. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Semin Hematol 2001; 38(S8): 15-21.
37. Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PCA et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieved complete cytogenetic remission with interferon-α. Br J Haematol 1995; 91: 126-131.
38. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
39. Hoepfl J, Miething C, Grundler R, Götze KS, Peschel C, Duyster J. Effects of imatinib on bone marrow engraftment in syngeneic mice. Leukemia 2002; 16: 1584-1588.
40. Fischer T, Reifenrath C, Hess GR, Corsetti MT, Kreil S, Beck J et al. Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Leukemia 2002; 16: 1220-1228.